Article Courtesy of PRNewswire and INVO Bioscience
MEDFORD, Mass. and SAN ANTONIO, Nov. 18, 2016 /PRNewswire/ — INVO Bioscience, Inc. (OTC: IVOB), a reproductive medical device company who was granted FDA clearance for the first Intravaginal Culture System, the INVOcell™, and Reproductive Medicine Associates of Texas (RMATX) today announced positive results of their initial eleven patients to receive the INVO™ procedure using the INVOcell device.
Dr. Francisco Arredondo of RMATX announced that he has nine (9) clinical pregnancies out of his first eleven (11) patients who have received the INVO procedure for treatment of infertility, or an 82% clinical pregnancy rate.
“I am extremely pleased with the results of the INVO procedure, and the patients have been very receptive to this new procedure,” commented Dr. Arredondo. “Patients perceive it as more organic and natural. We see very high quality embryo’s using the INVOcell, which has resulted in high pregnancy rates.”
Dr. Arredondo has been using the INVOcell in conjunction with a low ovarian stimulation protocol at 40% reduced cost compared to traditional IVF.
Dr. Arredondo is among the first physicians to adopt the INVO procedure in his practice. His team began a startup company in South Texas specifically focused on increasing the access to underserved communities due to economic barriers. S.M.A.R.T. IVF (Simple. Mindful. Affordable. Reproductive. Technology.) opened its doors in McAllen, Texas in October 2016.
Dr. Arredondo continued, “S.M.A.R.T. IVF is looking to increase the access to the dream of a family to people that before were unable to achieve due to cost barriers. We want to democratize fertility care.”
The patented INVO Procedure, is a fertility treatment that streamlines care, contributing to lower treatment costs compared to traditional IVF. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory petri dish, the INVOcell utilizes the women’s body as a natural incubator making it an in vivo procedure. The INVO fertility treatment in clinical studies produced live birth rates equivalent to traditional IVF while adding the benefits of a more natural, simpler and lower cost treatment.
“INVO Bioscience is thrilled to be partnering with Dr. Arredondo at RMATX, and we are exceedingly impressed with his very high clinical pregnancy rate,” commented Katie Karloff, CEO of INVO Bioscience.